Any current/future new fundraising through debt or equity?

There is no explicit mention of any new fundraising through debt or equity in the provided transcript. The company is currently focused on repaying existing acquisition-related debt, with repayments of INR1,250 crores done in April 2026, same amount due in October 2026, and INR2,500 crores scheduled for next year. The net debt to adjusted EBITDA ratio is targeted at 0.5x for FY27, indicating a focus on deleveraging rather than raising new debt. Capex plans include investment of up to INR500 crores in the Vadodara biotech facility through the subsidiary Mankind Medicare, but funding details are

Any current/future capex/capital investment/strategic investment?

Mankind Pharma approved an investment of up to INR 500 crores in its subsidiary, Mankind Medicare. This investment is primarily for setting up a best-in-class biotech facility in Vadodara. Capex spend in FY '26 was INR 737 crores, around 5.2% of total revenue, at the higher end of guidance. Capex guidance for FY '27 is expected to be 6% to 7% of FY '27 revenue, driven by enhanced R&D focus and specialized product development. New biotech facility in Vadodara aligns with the company's strategic emphasis on R&D and specialty products. The company remains on track to repay acquisition-related deb

Future growth expectations in sales/revenue/volumes?

Mankind Pharma expects double-digit top-line growth in FY27, aiming to outperform the IPM (Indian Pharmaceutical Market). Recovery in acute portfolio after muted FY26 performance, with sustained momentum in chronic therapies (cardiac, diabetes, respiratory). Increasing contribution from specialty and differentiated products including GLP-1 therapies. International business targeted for high teens to 20% growth driven by expansion in women healthcare, IVF products, and semi-regulated markets (Philippines, Malaysia, Africa). Modern trade in the OTC segment expected to sustain high teens growth a

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 revenue growth is expected to be double-digit and outperform the market, driven by recovery in acute therapies and sustained momentum in chronic and specialty products. EBITDA margin guidance for FY27 is 25.5% to 26.5%, slightly better than FY26's performance, which was around 25.4%. PAT is expected to improve with better EBITDA and controlled costs, following a marginal decline in FY26 primarily due to higher finance and depreciation costs. Earnings per share (EPS) growth outlook is positive, reflecting improved operating performance and margin expansion. The company aims to main

IN US

Mankind Pharma LtdQ1 FY27Pharmaceuticals & Biotechnology

Mankind Pharma Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,420P/E: 47.2Market Cap: ₹1.0L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Mankind Pharma expects double-digit top-line growth in FY27, aiming to outperform the IPM (Indian Pharmaceutical Market).
→Recovery in acute portfolio after muted FY26 performance, with sustained momentum in chronic therapies (cardiac, diabetes, respiratory).
→Increasing contribution from specialty and differentiated products including GLP-1 therapies.
→International business targeted for high teens to 20% growth driven by expansion in women healthcare, IVF products, and semi-regulated markets (Philippines, Malaysia, Africa).
→Modern trade in the OTC segment expected to sustain high teens growth after initial high base growth.
→Focus on expanding doctor prescriptions, increasing gynecologist coverage from 32,000 to 37,000, with 90% IVF center coverage.
→GLP-1 launch to be gradual, targeting endocrinologists initially; adjacent products like vitamins and minerals also prioritized for long-term growth.
→Consumer health segment expected to deliver double-digit growth backed by existing brand extensions and e-commerce expansion.

Margin guidance

Category 2

→FY27 revenue growth is expected to be double-digit and outperform the market, driven by recovery in acute therapies and sustained momentum in chronic and specialty products.
→EBITDA margin guidance for FY27 is 25.5% to 26.5%, slightly better than FY26's performance, which was around 25.4%.
→PAT is expected to improve with better EBITDA and controlled costs, following a marginal decline in FY26 primarily due to higher finance and depreciation costs.
→Earnings per share (EPS) growth outlook is positive, reflecting improved operating performance and margin expansion.
→The company aims to maintain employee cost around 22% of sales and keep SG&A expenditure stable without compromising growth.
→Long-term focus remains on profitable growth through specialty therapies, GLP-1 launches, and expansion in chronic therapies.
→Capex guidance for FY27 is 6-7% of revenue, supporting product and infrastructure expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company is currently focused on repaying existing acquisition-related debt, with repayments of INR1,250 crores done in April 2026, same amount due in October 2026, and INR2,500 crores scheduled for next year.
→The net debt to adjusted EBITDA ratio is targeted at 0.5x for FY27, indicating a focus on deleveraging rather than raising new debt.
→Capex plans include investment of up to INR500 crores in the Vadodara biotech facility through the subsidiary Mankind Medicare, but funding details are not specified as new fundraising.
→The overall tone suggests that the company is managing its existing financial commitments and investments without indicating new fundraising through debt or equity at this time.

Order book

The provided transcript and pages from Mankind Pharma Limited’s Q4 & FY26 earnings call do not mention any details about the current or expected order book or pending orders. There is no disclosure or discussion related to order backlog, pending orders, or order inflow status in the given content. The focus of the discussion is primarily on: - Acquisition integration and performance (Bharat Serum & Vaccines - BSV) - Business segments performance (acute, chronic, specialty, consumer health) - Cost optimization and R&D initiatives - Tax rate changes and financial outlook - Market share and growth strategies domestically and internationally If you need detailed order book or pending order information, it might be available in other financial disclosures or reports not included in this transcript.

Capex plans

Yes

→Mankind Pharma approved an investment of up to INR 500 crores in its subsidiary, Mankind Medicare.
→This investment is primarily for setting up a best-in-class biotech facility in Vadodara.
→Capex spend in FY '26 was INR 737 crores, around 5.2% of total revenue, at the higher end of guidance.
→Capex guidance for FY '27 is expected to be 6% to 7% of FY '27 revenue, driven by enhanced R&D focus and specialized product development.
→New biotech facility in Vadodara aligns with the company's strategic emphasis on R&D and specialty products.
→The company remains on track to repay acquisition-related debt by FY '28, alongside its capital investment plans.

How does Mankind Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Mankind Pharma Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Mankind Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio